This HTML5 document contains 115 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
n8	http://dx.doi.org/10.1200/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q43872776

rdf:type

wikibase:Item

schema:description

articolo scientifico научна статия artikulong pang-agham 2002年学术文章 2002年学术文章 наукова стаття, опублікована в лютому 2002 مقالة علمية نشرت في فبراير 2002 2002年学术文章 2002年學術文章 wissenschaftlicher Artikel scientific article published in February 2002 bài báo khoa học vitskapeleg artikkel 2002年学术文章 2002년 논문 videnskabelig artikel tudományos cikk teaduslik artikkel სამეცნიერო სტატია vetenskaplig artikel artikel ilmiah 2002年學術文章 научная статья scienca artikolo artículo científico publicado en 2002 мақолаи илмӣ научни чланак bilimsel makale 2002年學術文章 artigo científico articol științific vedecký článok artykuł naukowy บทความทางวิทยาศาสตร์ artigo científico научни чланак 2002年学术文章 2002年学术文章 2002年學術文章 ফেব্রুয়ারি ২০০২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ tieteellinen artikkeli artikull shkencor article scientifique 2002年學術文章 artículu científicu espublizáu en 2002 επιστημονικό άρθρο article científic vědecký článek scientific article published in February 2002 naučni članak artigo científico scientific article published in February 2002 article scientific vitenskapelig artikkel מאמר מדעי 2002 nî lūn-bûn 2002年の論文 wetenschappelijk artikel

p:P577

wds:Q43872776-3EA87D44-0196-4679-B831-AC524E9F927A

wdt:P577

2002-02-01T00:00:00Z

p:P407

wds:Q43872776-476BDB1D-8D26-436D-B216-4BE5A1F81855

wdt:P407

wd:Q1860

p:P2093

wds:Q43872776-3CD54F5F-C617-41BA-9670-3BDD50EEAD5A wds:Q43872776-5D0059BA-A011-445F-9422-E103B74CF6B9 wds:Q43872776-60184CD5-D28A-4395-95FA-F146792964DB wds:Q43872776-45C6E018-EDCE-485B-B88F-4FC37DD8C3EA wds:Q43872776-75780C7F-C7A3-4062-92AD-CD408ED11D84 wds:Q43872776-A1ADA18D-F2D4-4473-A0ED-4DEC34AB6F25 wds:Q43872776-A44E9D40-04B1-42A3-B1E1-144115A65A0B wds:Q43872776-899197C3-706C-4975-BFAE-C5D72C7A092D wds:Q43872776-8CCACD54-67C1-43FF-A994-6EA91CCD4EA7 wds:Q43872776-AD5E560C-C528-41E8-8B79-931571ACA9B5 wds:Q43872776-A56581DD-70F3-41E4-B928-BE97FE741DB8 wds:Q43872776-1472C5F9-F335-4E78-9D1F-817BEFC7D09E

wdt:P2093

M Moore I Wiznitzer J Shogan S E Jones F A Holmes T A Neumann L R Hill S Vukelja J Glaspy M Savin L Meza B C Liang

rdfs:label

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

skos:prefLabel

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

schema:name

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

p:P50

wds:Q43872776-BF54784A-F6B6-4514-AD14-EA64F1C9885A

wdt:P50

wd:Q88307619

p:P1476

wds:Q43872776-A578BAE7-A7B1-4A4A-8BA0-A2DC9F6379AE

wdt:P1476

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

p:P304

wds:Q43872776-3F7C34CD-73FB-439A-B5BC-2E1EDE1A63F8

wdt:P304

727-731

p:P31

wds:Q43872776-FFCEB0FF-B935-416C-B29B-E245ADA6A508

wdt:P31

wd:Q13442814

p:P921

wds:Q43872776-037D53B5-CF12-484B-9EA6-E6E438B0CAE8

wdt:P921

wd:Q974135

p:P698

wds:Q43872776-61A6E2AF-E67A-450B-8F4F-1CE6D5F4DCAC

wdtn:P698

n12:11821454

wdt:P698

11821454

p:P1433

wds:Q43872776-6EF6BE27-0B65-4CFF-9914-A79834563015

wdt:P1433

wd:Q400292

p:P433

wds:Q43872776-0E1B2604-9743-4719-A15C-2814F6B9702B

p:P478

wds:Q43872776-6A9EC5BF-854F-4083-8D52-41A9B45214F5

wdt:P433

3

wdt:P478

20

p:P356

wds:Q43872776-1EE31136-3F53-4075-96D9-702D9594BFDD

wdtn:P356

n8:JCO.20.3.727

wdt:P356

10.1200/JCO.20.3.727